Avodart Travel & Timezone-Shift Protocols: Dutasteride Dosing on the Road

What the label says about when to take it

Avodart is dutasteride 0.5 mg in a soft gelatin capsule, prescription only, and it is approved for symptomatic benign prostatic hyperplasia in men with an enlarged prostate [2][1]. The dosing instruction is one capsule once daily, swallowed whole rather than chewed or opened because contact with the contents can irritate the mouth and throat, with or without food [1]. Combination treatment is dutasteride 0.5 mg plus tamsulosin 0.4 mg, each once daily [1].

No clock time appears in that instruction. Food lowers the peak concentration by 10% to 15%, a change the label does not consider clinically significant [1].

The numbers behind the timing question

After an oral dose, dutasteride peaks in 2 to 3 hours, has an absolute bioavailability of about 60%, is 99.0% bound to albumin, and has a volume of distribution of 300 to 500 L [1]. It is metabolized by CYP3A4 and CYP3A5 and excreted mainly in feces, about 5% unchanged [1]. The terminal half-life at steady state is about 5 weeks; concentrations reach 65% of steady state after 1 month and about 90% after 3 months, with an average steady-state serum concentration of 40 ng/mL after 1 year [1].

The pharmacodynamic side is equally slow. Median serum DHT fell 85% after 1 week and 90% after 2 weeks of 0.5 mg daily, 94% at 1 year, and 93% to 95% through years 2 to 4, while median serum testosterone rose about 19% to 26% and stayed within the physiologic range [1].

For comparison, finasteride's half-life is about 5 to 6 hours against dutasteride's 5 weeks [1].

A PSA test taken mid-trip

Dutasteride lowers serum PSA by about 50% within 3 to 6 months. The Avodart label says a new PSA baseline should be established at least 3 months after starting treatment, with PSA monitored periodically thereafter [1]. The label also says that, to interpret an isolated PSA value in a man treated with Avodart for 3 months or more, the value should be doubled for comparison with normal values in untreated men, and that any confirmed increase from the lowest PSA value while on Avodart may signal prostate cancer and should be evaluated even if the level is still within the normal range for untreated men [1]. The free-to-total PSA ratio remains constant, and co-administration of dutasteride and tamsulosin results in similar changes to serum PSA as dutasteride alone [1]. The label notes that noncompliance with Avodart may also affect PSA test results [1].

Travel medicines that touch CYP3A4

Dutasteride is extensively metabolized by CYP3A4 and CYP3A5. The Avodart label advises caution in patients taking potent, chronic CYP3A4 enzyme inhibitors such as ritonavir, and states that the effect of potent CYP3A4 inhibitors on dutasteride has not been studied [1]. Verapamil and diltiazem decrease dutasteride clearance and lead to increased exposure, a change the label does not consider clinically significant and for which no dose adjustment is recommended [1]. The recommended Avodart dose is 0.5 mg once daily; in a label interaction study, a single 5 mg dose of Avodart followed 1 hour later by 12 g of cholestyramine did not affect dutasteride's relative bioavailability — 5 mg is not the recommended dose [1]. Dutasteride does not alter the steady-state pharmacokinetics of tamsulosin, terazosin, digoxin or warfarin [1].

Pregnant travel companions and the capsules

Avodart is contraindicated in pregnancy [1]. The label says women who are pregnant or may be pregnant should not handle Avodart capsules, because dutasteride can be absorbed through the skin and could result in unintended fetal exposure and potential risk to a male fetus. The label adds that if a pregnant woman comes in contact with leaking dutasteride capsules, the contact area should be washed immediately with soap and water [1].

Blood donation on a long trip

The Avodart label says men being treated with Avodart should not donate blood until at least 6 months have passed following their last dose, to prevent administration of dutasteride to a pregnant female transfusion recipient [1]. Serum concentrations stay detectable above 0.1 ng/mL for up to 4 to 6 months after stopping, and the elimination half-life is about 5 weeks [1]. The deferral runs from the last dose, not from departure.

Athletes: WADA status

Dutasteride and finasteride are not named in the WADA 2026 Prohibited List [3]. The only FDA-approved use of Avodart is symptomatic BPH in men with an enlarged prostate; androgenetic alopecia is off-label [1].